| Literature DB >> 32560188 |
Diego Fernández-Lázaro1, Cesar I Fernandez-Lazaro1,2, Juan Mielgo-Ayuso3, Lourdes Jiménez Navascués4, Alfredo Córdova Martínez3, Jesús Seco-Calvo5.
Abstract
Exercise overproduces oxygen reactive species (ROS) and eventually exceeds the body's antioxidant capacity to neutralize them. The ROS produce damaging effects on the cell membrane and contribute to skeletal muscle damage. Selenium (Se), a natural mineral trace element, is an essential component of selenoproteins that plays an important role in antioxidant defense. The activity of the enzyme glutathione peroxidase (GPx), a highly-efficient antioxidant enzyme, is closely dependent on the presence of Se. These properties of Se may be potentially applicable to improve athletic performance and training recovery. We systematically searched for published studies to evaluate the effectiveness of Se supplementation on antioxidant defense system, muscle performance, hormone response, and athletic performance among physically active individuals. We used the Preferred Reporting Elements for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and searched in SCOPUS, Web of Science (WOS), and PubMed databases to identify published studies until March 2020. The systematic review incorporated original studies with randomized controlled crossover or parallel design in which intake of Se administered once a day was compared with the same placebo conditions. No exclusions were applied for the type of physical exercise performed, the sex, nor the age of the participants. Among 150 articles identified in the search, 6 met the criteria and were included in the systematic review. The methodological quality of the studies was evaluated using the McMaster Critical Review Form. Oral Se supplementation with 180 µg/day or 240 µg/day (selenomethionine) and 200 µg/day (Sodium Selenite), significantly decreased lipid hydroperoxide levels and increased GPx in plasma, erythrocyte, and muscle. No significant effects were observed on athletic performance, testosterone hormone levels, creatine kinase activity, and exercise training-induced adaptations on oxidative enzyme activities or on muscle fiber type myosin heavy chain expression. In addition, Se supplementation showed to have a dampening effect on the mitochondria changes in chronic and acute exercise. In summary, the use of Se supplementation has no benefits on aerobic or anaerobic athletic performance but it may prevent Se deficiencies among athletes with high-intensity and high-volume training. Optimal Se plasma levels may be important to minimize chronic exercise-induced oxidative effects and modulate the exercise effect on mitochondrial changes.Entities:
Keywords: antioxidants; athletic performance; exercise; hormone response; mineral trace element; muscle; selenium
Mesh:
Substances:
Year: 2020 PMID: 32560188 PMCID: PMC7353379 DOI: 10.3390/nu12061790
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow-chart of the literature search and study selection.
Characteristics of participants and interventions in the studies included in the review.
|
| Active | 1 Study [ |
| Regularly trained athletes | 4 Studies [ | |
| No Regular Training before the Study | 1 Study [ | |
|
| 20–35 years | 5 Studies [ |
| Not Specified | 1 Study [ | |
|
| Assayed | 4 Studies [ |
| Not Assayed | 2 Studies [ | |
|
| Organic selenium in form of selenomethionine | 4 Studies [ |
| Salts of sodium selenite (Na2Se03) | 2 Studies [ | |
|
| 180 µg single dose | 3 Studies [ |
| 200 µg single dose | 2 Studies [ | |
| 240 µg single dose | 1 Study [ | |
|
| Daily | 6 Studies [ |
|
| 4 weeks | 1 Study [ |
| 10 weeks | 4 Studies [ | |
| 14 weeks | 1 Study [ |
Methodological quality of the studies included in the systematic review.
| References | Margaritis | Zamora | Savory | Tessier | Neek | Tessier | TI | |
|---|---|---|---|---|---|---|---|---|
| ITEMS |
| 1 | 1 | 1 | 1 | 1 | 1 | 6 |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 2 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 0 | 1 | 1 | 1 | 1 | 1 | 5 | |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
| TS | 12 | 13 | 14 | 13 | 15 | 13 | ||
| % | 75 | 81.3 | 87.5 | 81.3 | 93.8 | 81.3 | ||
| MQ | G | VG | VG | VG | E | VG | ||
(TS) Total items fulfilled by study. (1) Criterion met; (0) Criterion not met. (TI): Total items fulfilled by items. Methodological Quality (MQ): poor (P) ≤8 points; acceptable (A) 9–10 points; good (G) 11–12 points; very good (VG) 13–14 points; excellent (E) ≥15 points.
(A)
| Authors & Year | Study Design | Population | Intervention | Analyzed Results | Main Conclusions | |
|---|---|---|---|---|---|---|
| Savory et al., 2012 [ | Placebo-controlled, double-blind, crossover | 20 healthy subjects 9♂ & 1♀ | Supplementation: 200 μg Se (sodium selenite) once per day * 3 weeks’ placebo (not containing glucose) during another 3-week period. | [Se] | Post Se treatment period ↑ *[Se] NW & OW compared to week 0 | |
| Post Se treatment period ↑* [Se] NW & OW compared to placebo treatment | ||||||
| TAS, GSH, SOD | Placebo period & Se treatment period rest vs. post PhA: OW & NW ↔ TAS; GSH; SOD OW vs. NW ↔ TAS; GSH; SOD | |||||
| LH | Placebo period rest vs. post PhA: OW ↑*LH NW ↑LH OW vs. NW ↑*LH | |||||
| Se treatment period rest vs. post PhA: OW †LH NW †LH − OW vs. NW †LH | ||||||
| Placebo vs. Se treatment post PhA: OW ↓*LH; NW↔LH | ||||||
| Tessier et al., 1994 [ | Placebo-controlled, double-blind, randomized | 24 ♂ healthy students | Supplementation: 180 μg Se (Seleniomethionine) once per day * 10-week period | Pre-PhA vs. Post-PhA | SeG vs. PbG | |
| [Se] | ↑*[Se] SeG ↓[Se] PbG | # [Se] | ||||
| GTtotal | ↓* SeGr ↓* PbGr | † GTtotal | ||||
| GSSG | ↓ GSSG SeGr ↓ GSSG PbGr | † GSSG | ||||
| GPx plasma | ↑* SeG ↑PbG | # GPx | ||||
| EGPx | ↑* SeG ↑PbG | # EGPx | ||||
| EGR | ↑* SeG ↑*PbG | † EGR | ||||
| Vitamin E | ↓SeG ↑PbG | † Vitamin E | ||||
| VO2max | ↑* SeG ↑*PbG | † VO2max | ||||
| SeG: ↑ VO2max positive correlated ↑GPX (r:0.66 | ||||||
(B)
| Author/s—Year | Study Design | Population | Intervention | Analyzed Results | Results and Main Conclusions | |
|---|---|---|---|---|---|---|
| Neek et al., 2011 [ | Placebo-controlled, double-blind, randomized | 16 ♂ road cyclists | Supplementation: 200 μg de Selenium (sodium selenite) once per day * 4-week period | Pre-PhA vs. Post-PhA | SeG vs. PbG | |
| Tt | ↑* SeG ↑* PbG | ↔ Tt | ||||
| Tf | ↑* SeG ↑* PbG | ↔ Tf | ||||
| [La] | ↑* SeG ↑* PbG | ↔ [La] | ||||
| Margaritis et al., 1997 [ | Placebo-controlled, double-blind, randomized | 24 ♂ healthy subjects | Supplementation: 180 μg Se (Seleniomethionine) once per day * 10-week period | Pre-PhA vs. Post-PhA | SeG vs. PbG | |
| [Se] | ↑*[Se] SeG ↓[Se] PbG | # SeG vs. PbG | ||||
| GPx plasma | ↑*SeG ↑PbG | # SeG vs. PbG | ||||
| GPx muscle | ↓ SeG ↓ PbG | † SeG vs. PbG | ||||
| Vitamin E | ↓ SeG ↑PbG | † SeG vs. PbG | ||||
| CK | ↓ SeG ↓PbG | † SeG vs. PbG | ||||
| Cyt Ox | ↑ SeG ↑PbG | # SeG vs. PbG | ||||
| SDH | ↑ SeG ↑ PbG | † SeG vs. PbG | ||||
| MHC I | ↑SeG ↑PbG | # SeG vs. PbG | ||||
| MHC II | ↓SeG ↓PbG | † SeG vs. PbG | ||||
| MHC I - MHC II co-expressed | ↑SeG ↑PbG | # SeG vs. PbG | ||||
| VO2max | ↑*SeG ↑*PbG | # SeG vs. PbG | ||||
| VO2total | ↑*SeG ↑*PbG | # SeG vs. PbG | ||||
(C)
| Author/s—Year | Study Design | Population | Intervention | Analyzed Results | Main Conclusions | |||
|---|---|---|---|---|---|---|---|---|
| Zamora et al., 1995 [ | Placebo-controlled, double-blind, randomized | 24 ♂ healthy students; | Supplementation: 180 μg Se (Seleniomethionine) once per day * 10-week period | At rest | Post-PhA | |||
| Pre-PhA vs. Post-PhA | SeG vs. PbG | Pre-PhA vs. Post-PhA | SeG vs. PbG | |||||
| Muscle mitochondria morphometric parameters | ↑*SelG ↔ PbG | #SelGr vs PbG | ↑*SelG ↔ PbG | #SelGr vs PbG | ||||
| VO2max | ↔ SelGr ↔ PbG | † SelGr vs PbG | ↔ SelGr ↔ PbG | † SelGr vs PbG | ||||
| Body fat % | ↔ SelGr ↔ PbG | † SelGr vs PbG | ↔ SelGr ↔ PbG | † SelGr vs PbG | ||||
| BMI Kg*m2 | ↔ SelGr ↔ PbG | † SelGr vs PbG | ↔ SelGr ↔ PbG | † SelGr vs PbG | ||||
| Tessier et al., 1995 [ | Placebo-controlled, double-blind, randomized | 24 ♂ healthy; | Supplementation: 240 μg organic selenium (70% selenomethionine) Selenion® once per day *10-week period | Pre-PhA vs. Post-PhA | SeG vs. PbG | |||
| [Se] | ↑*SelG ↓PbG | † SelGr vs PbG | ||||||
| Vitamin E | ↓SelG ↑PbG | † SelGr vs PbG | ||||||
| GPx muscle | ||||||||
| PhA cronic | ↓SelG ↓PbG | † SelGr vs PbG | ||||||
| PhA acute | ↑*SelG ↓*PbG | # SelGr vs PbG | ||||||
♂: Men; ♀: Women; NW: Normal weight; OW: Over weight; y: Years; Kg: Kilograms; m: Meters; cm: Centimeters; BMI: Body mass index; PhA: Physical activity; Se: Selenium; [Se]: Plasma Selenium levels; ↑*: Statistically significant increase; ↑: Non-statistical increase; ↓*: Statistically significant decrease; ↓: Non-statistical decrease; †: Change without statistical significance; #: Change statistical significance; ↔: Without changes; LH: Lipid hydroperoxidase; GSH: Reduced glutathione; SOD: Superoxide dismutase; TAS: Total antioxidant status; PbG: Placebo group; SeG: Selenium group; GTtotal: Glutathione total; GSSG: Glutathione oxidized; GPx: Glutathione peroxidase; EGPx: Erythrocyte glutathione peroxidase; EGR: Erythrocyte glutathione reductase; VO2max: Maximum oxygen consumption; Tt: Total testosterone; Tf: Testosterone free; [La]: Plasma lactate; CK: Creatine kinase; Cyt Ox: Cytochrome C oxidase; SDH: Succinate dehydrogenase; MCH: Myosin heavy chains; QA: Density of the mitochondria profile; Aa: surface of all the mitochondria profile area; â: mean surface of individual mitochondria profile area.